Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis

Phase 2 Active not recruiting 42 enrolled Imperial College London AstraZeneca · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

RACEMATE is a phase 2b, multicentre, randomised, double-blinded, placebo-controlled study designed to explore the efficacy and mechanism of action of tezepelumab in adults with eosinophilic granulomatosis with polyangiitis (EGPA).

Timeline

Start: 2024-05-15
Primary completion: 2026-09
Completion: 2026-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tezepelumab	Monoclonal antibody	210 mg	Subcutaneous

Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis

Summary

Timeline

Drugs

Indications